AIAISci
中文
clinical updateBiotech

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Clinical/translation signal: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Occurred SourceClinicalTrials.govapprovedSourceClinicalTrials.gov

Factual summary

What happened

ClinicalTrials.gov registry update for Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

SourceClinicalTrials.gov

Why it matters

Clinical trial registry updates are translation signals, not commercialization claims by themselves.

SourceClinicalTrials.gov

Limitations

ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

SourceClinicalTrials.gov

Linked output

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinomaclinical trial

People

No reviewed person relationship is attached to this event.

Organizations

National Cancer Institute (NCI)

Topics

No reviewed topic relationship is attached to this event.

Problems

No reviewed problem relationship is attached to this event.

Relationship evidence

Timeline

  1. clinical updateTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
    SourceClinicalTrials.gov